Philippe Jaoude1, Thomas Kufel, Ali A El-Solh. 1. VA Western New York Healthcare System, Medical Research, Bldg. 20 (151) VISN02, 3495 Bailey Avenue, Buffalo, NY, 14215-1199, USA.
Abstract
BACKGROUND: Patients with the combination of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), known as the "overlap syndrome," have a substantially greater risk of morbidity and mortality compared to those with either COPD or OSA alone. The study's objective was to report on the long-term outcome of hypercapnic (PaCO2 ≥ 45 mmHg) and normocapnic patients with the overlap syndrome treated with continuous positive airway pressure (CPAP). METHODS: A nonconcurrent cohort of consecutive patients with the overlap syndrome was followed for a median duration of 71 months (range 1-100) at a VA sleep center. All patients were managed according to the prevailing recommendations of both diseases. The end point of the study was all-cause mortality. RESULTS: Of the 271 patients identified, 104 were hypercapnic (PaCO2 = 51.6 ± 4.3 mmHg). Both normocapnic and hypercapnic patients had comparable apnea-hypopnea indexes (AHI) (29.2 ± 23.8 and 35.2 ± 29.2/h, respectively; p = 0.07) and similar adherence rates to CPAP (43 and 42 %, respectively, p = 0.9). Survival analysis revealed that hypercapnic patients who were adherent to CPAP had reduced mortality compared to nonadherent hypercapnic patients (p = 0.04). In contrast, the cumulative mortality rate for normocapnic patients was not significantly different between the adherent and the nonadherent group (p = 0.42). In multivariate analysis, the comorbidity index was the only independent predictor of mortality in normocapnic patients with the overlap syndrome [hazard ratio (HR) 1.68; p < 0.001] while CPAP adherence was associated with improved survival (HR 0.65; p = 0.04). CONCLUSIONS: CPAP mitigates the excess risk of mortality in hypercapnic patients but not in normocapnic patients with the overlap syndrome.
BACKGROUND:Patients with the combination of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), known as the "overlap syndrome," have a substantially greater risk of morbidity and mortality compared to those with either COPD or OSA alone. The study's objective was to report on the long-term outcome of hypercapnic (PaCO2 ≥ 45 mmHg) and normocapnic patients with the overlap syndrome treated with continuous positive airway pressure (CPAP). METHODS: A nonconcurrent cohort of consecutive patients with the overlap syndrome was followed for a median duration of 71 months (range 1-100) at a VA sleep center. All patients were managed according to the prevailing recommendations of both diseases. The end point of the study was all-cause mortality. RESULTS: Of the 271 patients identified, 104 were hypercapnic (PaCO2 = 51.6 ± 4.3 mmHg). Both normocapnic and hypercapnic patients had comparable apnea-hypopnea indexes (AHI) (29.2 ± 23.8 and 35.2 ± 29.2/h, respectively; p = 0.07) and similar adherence rates to CPAP (43 and 42 %, respectively, p = 0.9). Survival analysis revealed that hypercapnic patients who were adherent to CPAP had reduced mortality compared to nonadherent hypercapnic patients (p = 0.04). In contrast, the cumulative mortality rate for normocapnic patients was not significantly different between the adherent and the nonadherent group (p = 0.42). In multivariate analysis, the comorbidity index was the only independent predictor of mortality in normocapnic patients with the overlap syndrome [hazard ratio (HR) 1.68; p < 0.001] while CPAP adherence was associated with improved survival (HR 0.65; p = 0.04). CONCLUSIONS: CPAP mitigates the excess risk of mortality in hypercapnic patients but not in normocapnic patients with the overlap syndrome.
Authors: R D McEvoy; R J Pierce; D Hillman; A Esterman; E E Ellis; P G Catcheside; F J O'Donoghue; D J Barnes; R R Grunstein Journal: Thorax Date: 2009-02-12 Impact factor: 9.139
Authors: H F Becker; A J Piper; W E Flynn; S G McNamara; R R Grunstein; J H Peter; C E Sullivan Journal: Am J Respir Crit Care Med Date: 1999-01 Impact factor: 21.405
Authors: M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer Journal: Thorax Date: 2003-09 Impact factor: 9.139
Authors: Sergio Martinez; Jamie Sullivan; Cara Pasquale; Bill Clark; Elisha Malanga; Sean Deering; Lin Liu; Carl J Stepnowsky Journal: Chronic Obstr Pulm Dis Date: 2022-07-29
Authors: Rodolfo Augusto Bacelar de Athayde; José Ricardo Bandeira de Oliveira Filho; Geraldo Lorenzi Filho; Pedro Rodrigues Genta Journal: J Bras Pneumol Date: 2018 Nov-Dec Impact factor: 2.624
Authors: Hyun Woo Lee; Sun Mi Choi; Jinwoo Lee; Young Sik Park; Chang-Hoon Lee; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Sang-Min Lee Journal: Acute Crit Care Date: 2019-08-31
Authors: Jeremy E Orr; Christopher N Schmickl; Bradley A Edwards; Pamela N DeYoung; Rebbecca Brena; Xiaoying S Sun; Sonia Jain; Atul Malhotra; Robert L Owens Journal: Physiol Rep Date: 2020-02
Authors: Madalina Macrea; Simon Oczkowski; Bram Rochwerg; Richard D Branson; Bartolome Celli; John M Coleman; Dean R Hess; Shandra Lee Knight; Jill A Ohar; Jeremy E Orr; Amanda J Piper; Naresh M Punjabi; Shilpa Rahangdale; Peter J Wijkstra; Susie Yim-Yeh; M Bradley Drummond; Robert L Owens Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405